ClinicalTrials.gg
CompletedNCT04443244Updated Nov 16, 2021

Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy

A Phase 2 interventional study of Botulinum Toxin Type A Injection (Botulax®) 24Units and Botulinum Toxin Type A Injection (Botulax®) 48Units in Benign Masseteric Hypertrophy, sponsored by Hugel. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-11-16.

Sponsored by Hugel · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy

Read the detailed description

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase Ⅱ Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy

02

Conditions studied

  • Benign Masseteric Hypertrophy
03

In context

Lead sponsor

Hugel is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and Female adults aged 19 or older.
  2. Sighting, facilitation measurement are judged by the investigator to be the ratio of Benign Masseteric Hypertrophy.
  3. Subject who understand and willing to perform with the procedures and visiting schedules of clinical trial.
  4. Subject who voluntarily agree to participate in this clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Subject who is facial asymmetry in visual measurement by the investigator.
  2. Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate .
  3. Subject who is deemed unable to participate in a clinical trial under the judgement of a Investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Botulinum Toxin Type A(Botulax®) 24Units

    Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.

    Drug: Botulinum Toxin Type A Injection (Botulax®) 24Units

  • Experimental
    Botulinum Toxin Type A(Botulax®) 48Units

    Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.

    Drug: Botulinum Toxin Type A Injection (Botulax®) 48Units

  • Experimental
    Botulinum Toxin Type A(Botulax®) 72Units

    Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.

    Drug: Botulinum Toxin Type A Injection (Botulax®) 72Units

  • Experimental
    Botulinum Toxin Type A(Botulax®) 96Units

    Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.

    Drug: Botulinum Toxin Type A Injection (Botulax®) 96Units

  • Placebo comparator
    Placebo(Normal Saline)

    Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.

    Other: Normal Saline

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of change from baseline in masseter muscle thickness during maximum clenching

    Amount of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography

    Time frame: Baseline to week 12

Secondary outcomes

  1. Amount of change from baseline in masseter muscle thickness during maximum clenching

    Amount of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography

    Time frame: Baseline to week 4, 8, 16

  2. Rate of change from baseline in masseter muscle thickness during maximum clenching

    Rate of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography

    Time frame: Baseline to week 4, 8, 12, 16

  3. Amount of change from baseline in masseter muscle thickness during resting

    Amount of change from baseline in masseter muscle thickness during resting by Ultrasonography

    Time frame: Baseline to week 4, 8, 12, 16

  4. Rate of change from baseline in masseter muscle thickness during resting

    Rate of change from baseline in masseter muscle thickness during resting by Ultrasonography

    Time frame: Baseline to week 4, 8, 12, 16

  5. Amount and rate of change from baseline in lower face volume during maximum clenching

    Amount and rate of change from baseline in lower face volume during maximum clenching by 3D imaging

    Time frame: Baseline to week 4, 8, 12, 16

  6. Overall improvement of Investigator

    Overall improvement of Investigator by assessment scale

    Time frame: Baseline to week 4, 8, 12, 16

  7. Overall satisfaction of subject

    Subject satisfaction assessment using a scale ranging from Extremely dissatisfied to Extremely satisfied by questionnaire

    Time frame: Baseline to week 4, 8, 12, 16

07

Study locations

1 site
  • Hugel
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Nov 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2020
First posted
Jun 23, 2020
StartActual
May 27, 2020
Primary completionActual
Nov 18, 2020
CompletionActual
Jul 16, 2021
Last update
Nov 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04443244
Lead sponsor
Hugel
Responsible party
Sponsor
First posted
Jun 23, 2020
Start date
May 27, 2020
Primary completion
Nov 18, 2020
Completion
Jul 16, 2021
Last update
Nov 16, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion